All In Biotech

Drug Trial Radar · NCT07494045

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

An Open-Label, Randomized, Multiple-Dose, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of CTAP101 Extended-release Capsules in Pediatric Participants <18 Years of Age With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Oct 2027

Study completion Aug 2028

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are: 1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules 2. To investigate the safety and tolerability of CTAP101 Capsules Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.

Conditions

  • CKD Stage 3
  • CKD Stage 4
  • Secondary Hyperparathyroidism
  • VDI

Interventions

  • CTAP101Drug

    Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Apparent clearance (CL/F)Time frame: Up to 14 weeks
  2. Volume of distribution (Vd/F)Time frame: Up to 14 weeks
  3. Terminal elimination half-life (t1/2)Time frame: Up to 14 weeks
  4. Incidence of treatment emergent adverse events (TEAE)Time frame: Up to 14 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • OPKO Site

    Kansas City, Missouri · Not yet recruiting

  • OPKO Site

    Columbus, Ohio · Not yet recruiting

  • OPKO Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • OPKO Site

    Greenville, South Carolina · Recruiting

  • OPKO Site

    Madison, Wisconsin · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.